Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 62

Sort by

Sort Order Select

Journal Articles

The Molecular Characteristics and Clinical Relevance of NUP98 -Other Translocations in Pediatric Acute Myeloid Leukemia

Eline J.M. Bertrums, Jenny L. Smith, MSc, MD, Rhonda E. Ries, MA, Todd A. Alonzo, PhD, Fabiana Ostronoff, MD, Gertjan J.L. Kaspers, Prof. MD PhD, Henrik Hasle, PhD, Christian M. Zwaan, Betsy A Hirsch, PhD, Susana C. Raimondi, PhD, Todd M. Cooper, DO, Richard Aplenc, MD PhD, Alan S. Gamis, MD MPH, Edward A. Kolb, MD, Bianca F. Goemans, MD PhD, Soheil Meshinchi, MDPhD

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-137537

Published: 2020

Journal Articles

Genome and Transcriptome Profiling of Monosomy 7 AML Defines Novel Risk and Therapeutic Cohorts

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-137244

Published: 2020

Journal Articles

Structural Variants Involving MLLT10/AF10 Are Associated with Adverse Outcome in AML Regardless of the Partner Gene - a COG/Tpaml Study

Rhonda E. Ries, MA, Amanda R. Leonti, MS, Timothy Junius Triche, Jr., PhD, Robert B. Gerbing, Betsy A Hirsch, PhD, Susana C. Raimondi, PhD, Jenny L. Smith, MSc, MD, Todd M Cooper, DO, Jason E. Farrar, MD, Aniruddha J. Deshpande, E. Anders Kolb, MD, Alan S Gamis, MD MPH, Richard Aplenc, MD PhD, Todd A. Alonzo, PhD, Soheil Meshinchi, MD PhD

Blood (2019) 134 (Supplement_1): 461.

https://doi.org/10.1182/blood-2019-125943

Published: 2019

Journal Articles

Sorafenib in Combination with Standard Chemotherapy for Children with High Allelic Ratio FLT3/ITD+ AML Improves Event-Free Survival and Reduces Relapse Risk: A Report from the Children's Oncology Group Protocol AAML1031

Jessica A. Pollard, MD, Todd A. Alonzo, PhD, Patrick A. Brown, MD, Robert B. Gerbing, Elizabeth Fox, MD, John Kim Choi, MD, Brian T. Fisher, DO, MSCE, Betsy A Hirsch, PhD, Samir Kahwash, MD, John E. Levine, MDMS, Michael R. Loken, PhD, Susana C. Raimondi, PhD, Katherine Tarlock, MD, Andrew C. Wood, MBCHB, Lillian Sung, MD PhD, Anders E. Kolb, MD, Alan S Gamis, MD MPH, Soheil Meshinchi, MD PhD, Richard Aplenc, MD PhD

Blood (2019) 134 (Supplement_1): 292.

https://doi.org/10.1182/blood-2019-129557

Published: 2019

Journal Articles

High-Dose Cytarabine Is Indispensable for the Survival of Children with Myeloid Leukemia of Down Syndrome Despite Negative Minimal Residual Disease Post-Induction

Johann K. Hitzler, MD, Jason Berman, MD, Robert B. Gerbing, Amy Beckman, Betsy A Hirsch, PhD, Susana C. Raimondi, PhD, Todd E Druley, MD PhD, Michael R. Loken, PhD, Lisa Eidenschink Brodersen, PhD, Karen Chisholm, Shelton A. Viola, MD, Jeffrey W. Taub, MD, Alan S Gamis, MD MPH, Todd A. Alonzo, PhD, E. Anders Kolb, MD

Blood (2019) 134 (Supplement_1): 118.

https://doi.org/10.1182/blood-2019-126723

Published: 2019

Journal Articles

History of Autoimmune Disease Is Associated with Increased Risk for Myelodysplastic Syndromes

Michelle A. Roesler, BS, Amy Linabery, PhD MS, Michaela Richardson, MPH, Adina Cioc, MD, Betsy A Hirsch, PhD, Phuong L. Nguyen, MD, Erica D. Warlick, MD, Jenny Poynter, PhD

Blood (2019) 134 (Supplement_1): 3014.

https://doi.org/10.1182/blood-2019-130940

Published: 2019

Journal Articles

Factors Predicting Early Mortality in Newly Diagnosed Myelodysplastic Syndrome (MDS): A Population Based Study

Annie M. Jacobsen, MD, Jenny Poynter, PhD, Michaela Richardson, MPH, Phuong L. Nguyen, MD, Betsy A Hirsch, PhD, Adina Cioc, MD, Michelle A. Roesler, BS, Erica D. Warlick, MD

Blood (2018) 132 (Supplement 1): 4369.

https://doi.org/10.1182/blood-2018-99-112319

Published: 2018

Journal Articles

CD33-Single Nucleotide Polymorphism (CD33-SNP) Score Predicts Gemtuzumab Ozogamicin Response in Childhood Acute Myeloid Leukemia: Report from Children's Oncology Group AAML0531 Trial

Jatinder Lamba, PhD, Lata Chauhan, PhD, Miyoung Shin, PhD, Michael R. Loken, PhD, Jessica A. Pollard, MD, Jim Wang, Richard Aplenc, MD, Betsy A Hirsch, PhD, Susana C. Raimondi, PhD, Roland B. Walter, MD PhD, Irwin D. Bernstein, MD, Alan S Gamis, MD MPH, Todd A Alonzo, PhD, Soheil Meshinchi, MD PhD

Blood (2017) 130 (Supplement 1): 3826.

https://doi.org/10.1182/blood.V130.Suppl_1.3826.3826

Published: 2017

Journal Articles

Revised Risk Stratification Criteria for Children with Newly Diagnosed Acute Myeloid Leukemia: A Report from the Children's Oncology Group

Todd M Cooper, DO, Rhonda E. Ries, MA, Todd A Alonzo, PhD, Robert B Gerbing, Michael R. Loken, PhD, Lisa E. Brodersen, PhD, Susana C. Raimondi, PhD, Betsy A Hirsch, PhD, Richard Aplenc, MD, Alan S Gamis, MD MPH, Edward A Kolb, MD, Soheil Meshinchi, MD PhD

Blood (2017) 130 (Supplement 1): 407.

https://doi.org/10.1182/blood.V130.Suppl_1.407.407

Published: 2017

Journal Articles

Functional Properties of Exon 17 KIT Mutations in Pediatric CBF AML Predict for Inferior Outcome and Enhanced Response to Tyrosine Kinase Inhibition: A Report from the Children's Oncology Group

Katherine Tarlock, MD, Todd A Alonzo, PhD, Robert B Gerbing, Yi-Cheng Wang, Rhonda E. Ries, MA, Tiffany Hylkema, BS, Jason Joaquin, Susana C. Raimondi, PhD, Betsy A Hirsch, PhD, Edward A Kolb, MD, Alan S Gamis, MD MPH, Soheil Meshinchi, MD PhD, Jessica A. Pollard, MD

Blood (2017) 130 (Supplement 1): 25.

https://doi.org/10.1182/blood.V130.Suppl_1.25.25

Published: 2017

Journal Articles

Distinct Outcome Based on Fusion Transcript in t(16;21) Rearranged Pediatric AML, a Collaborative Retrospective Analysis By the I-BFM SG

Blood (2017) 130 (Supplement 1): 184.

https://doi.org/10.1182/blood.V130.Suppl_1.184.184

Published: 2017

Journal Articles

Drug Transporter ABCB1 SNP Predicts Outcome in Patients with Acute Myeloid Leukemia Treated with Gemtuzumab Ozagamicin: A Report from Children's Oncology Group AAML0531 Trial

Lata Chauhan, PhD, Todd A Alonzo, PhD, Jim Wang, Michael R. Loken, PhD, Jessica A. Pollard, MD, Richard Aplenc, MD, Susana C. Raimondi, PhD, Roland B. Walter, MD PhD, Betsy A Hirsch, PhD, Irwin D. Bernstein, MD, Alan S Gamis, MD MPH, Soheil Meshinchi, MD PhD, Jatinder Lamba, PhD

Blood (2017) 130 (Supplement 1): 2526.

https://doi.org/10.1182/blood.V130.Suppl_1.2526.2526

Published: 2017

Journal Articles

Characteristics and Outcomes of Pediatric Patients with t(16;16)-AML: Results of a Case Series By the International BFM Study Group

Kim Klein, MD MSc, Valerie de Haas, MD PhD, Jonas Abrahamsson, MD PhD, Todd A Alonzo, PhD, Brenda Gibson, MD PhD, Christine J Harrison, PhD FRCPath, Henrik Hasle, MD PhD, Betsy A Hirsch, PhD, Guy Leverger, MD PhD, Franco Locatelli, MD PhD, Susana C. Raimondi, PhD, Jeffrey E Rubnitz, MD PhD, Dirk Reinhardt, MD PhD, Daisuke Tomizawa, MD PhD, Gertjan J.L. Kaspers, MD PhD

Blood (2017) 130 (Supplement 1): 2671.

https://doi.org/10.1182/blood.V130.Suppl_1.2671.2671

Published: 2017

Journal Articles

CD33 Splicing Polymorphism Is a Strong Predictor of Therapeutic Efficacy of Gemtuzumab Ozogamicin in De Novo AML: Report from COG-AAML0531 Study

Jatinder K Lamba, PhD, Lata Chauhan, PhD, Michael R. Loken, PhD, Jessica Pollard, MD, Yi-Cheng Wang, MS, Ries E Rhonda, Richard Aplenc, MD PhD, Betsy A. Hirsch, PhD, Susana C. Raimondi, PhD, Roland B. Walter, MD PhD, Irwin D. Bernstein, MD, Alan S. Gamis, MD MPH, Todd A. Alonzo, PhD, Soheil Meshinchi, MD PhD

Blood (2016) 128 (22): 2743.

https://doi.org/10.1182/blood.V128.22.2743.2743

Published: 2016

Journal Articles

Prognostic Significance of 11q23/ MLL Fusion Partners in Children with Acute Myeloid Leukemia (AML) - Results from the Children's Oncology Group (COG) Trial AAML0531

Erin M. Guest, MD, Betsy A. Hirsch, PhD, E. Anders Kolb, MD, Todd A. Alonzo, PhD, Robert Gerbing, BS, Richard Aplenc, MD PhD, Jessica Pollard, MD, Lillian Sung, MD PhD FRCPC, Soheil Meshinchi, MD PhD, Alan S. Gamis, MD MPH, Susana C. Raimondi, PhD

Blood (2016) 128 (22): 1211.

https://doi.org/10.1182/blood.V128.22.1211.1211

Published: 2016

Journal Articles

Alteration of Chromatin Modifiers and Misregulation of Transcription Factors Define the Genomic Profile of Infant AML

Rhonda E. Ries, MA, Hamid Bolouri, PhD, Jason E Farrar, MD, Emilia L. Lim, PhD, Timothy Junius Triche, Jr., PhD, Katherine Tarlock, MD, Jaime Guidry Auvil, PhD, Betsy A. Hirsch, PhD, Susana C. Raimondi, PhD, Yussanne Ma, PhD, Marco A. Marra, PhD, Richard Aplenc, MD PhD, Erin M. Guest, MD, E. Anders Kolb, MD, Alan S. Gamis, MD MPH, Malcolm A. Smith, MD PhD, Daniela S. Gerhard, PhD, Soheil Meshinchi, MD PhD

Blood (2016) 128 (22): 774.

https://doi.org/10.1182/blood.V128.22.774.774

Published: 2016

Journal Articles

The Addition of Bortezomib to Standard Chemotherapy for Pediatric Acute Myeloid Leukemia Has Increased Toxicity without Therapeutic Benefit: A Report from the Children's Oncology Group

Richard Aplenc, MD PhD, Soheil Meshinchi, MD PhD, Lillian Sung, MD PhD FRCPC, Todd A. Alonzo, PhD, Jessica Pollard, MD, Robert Gerbing, BS, Susana C. Raimondi, PhD, Betsy A. Hirsch, PhD, Michael R. Loken, PhD, Laura Winter, PharmD, Samir B. Kahwash, John K Choi, MD, John E Levine, MD MS, E. Anders Kolb, MD, Alan S. Gamis, MD MPH

Blood (2016) 128 (22): 899.

https://doi.org/10.1182/blood.V128.22.899.899

Published: 2016

Journal Articles

Recurrent Genetic Abnormalities Are Reflected in Phenotype at Diagnosis in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group Protocol AAML0531

Andrew P. Voigt, Lisa Eidenschink Brodersen, PhD, Robert B. Gerbing, MA, Andrew J. Menssen, Betsy A. Hirsch, PhD, Susana C. Raimondi, PhD, Alan S. Gamis, MD MPH, Todd A. Alonzo, PhD, Soheil Meshinchi, MD PhD, Michael R. Loken, PhD

Blood (2015) 126 (23): 1377.

https://doi.org/10.1182/blood.V126.23.1377.1377

Published: 2015

Journal Articles

High Expression of Myocyte Enhancer Factor 2C ( MEF2C ) Is Associated with Adverse Risk Features and Poor Outcome in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group

George S. Laszlo, PhD, Todd A. Alonzo, PhD, Chelsea J. Gudgeon, BS, Kimberly H. Harrington, BS, Alex Kentsis, MD PhD, Robert B. Gerbing, MA, Yi-Cheng Wang, MS, Rhonda E. Ries, MA, Susana C. Raimondi, PhD, Betsy A. Hirsch, PhD, Alan S. Gamis, MD MPH, Soheil Meshinchi, MD PhD, Roland B. Walter, MD PhD MS

Blood (2015) 126 (23): 2570.

https://doi.org/10.1182/blood.V126.23.2570.2570

Published: 2015

Journal Articles

Prevalence and Prognostic Significance of KIT Mutations in Pediatric Core Binding Factor AML Patients Treated with Gemtuzumab Ozogamicin: Results from the Randomized Phase III Children's Oncology Group Trial AAML0531

Jessica Pollard, MD, Todd A. Alonzo, PhD, Robert B. Gerbing, MA, Yi-Cheng Wang, MS, Jason Joaquin, Susana C. Raimondi, PhD, Betsy A. Hirsch, PhD, Lillian Sung, MD PhD, Richard Aplenc, MD PhD, Irwin D. Bernstein, MD, Alan S. Gamis, MD MPH, Soheil Meshinchi, MD PhD

Blood (2015) 126 (23): 800.

https://doi.org/10.1182/blood.V126.23.800.800

Published: 2015

NARROW

The Molecular Characteristics and Clinical Relevance of NUP98 -Other Translocations in Pediatric Acute Myeloid Leukemia

Genome and Transcriptome Profiling of Monosomy 7 AML Defines Novel Risk and Therapeutic Cohorts

Structural Variants Involving MLLT10/AF10 Are Associated with Adverse Outcome in AML Regardless of the Partner Gene - a COG/Tpaml Study

Sorafenib in Combination with Standard Chemotherapy for Children with High Allelic Ratio FLT3/ITD+ AML Improves Event-Free Survival and Reduces Relapse Risk: A Report from the Children's Oncology Group Protocol AAML1031

High-Dose Cytarabine Is Indispensable for the Survival of Children with Myeloid Leukemia of Down Syndrome Despite Negative Minimal Residual Disease Post-Induction

History of Autoimmune Disease Is Associated with Increased Risk for Myelodysplastic Syndromes

Factors Predicting Early Mortality in Newly Diagnosed Myelodysplastic Syndrome (MDS): A Population Based Study

CD33-Single Nucleotide Polymorphism (CD33-SNP) Score Predicts Gemtuzumab Ozogamicin Response in Childhood Acute Myeloid Leukemia: Report from Children's Oncology Group AAML0531 Trial

Revised Risk Stratification Criteria for Children with Newly Diagnosed Acute Myeloid Leukemia: A Report from the Children's Oncology Group

Functional Properties of Exon 17 KIT Mutations in Pediatric CBF AML Predict for Inferior Outcome and Enhanced Response to Tyrosine Kinase Inhibition: A Report from the Children's Oncology Group

Distinct Outcome Based on Fusion Transcript in t(16;21) Rearranged Pediatric AML, a Collaborative Retrospective Analysis By the I-BFM SG

Drug Transporter ABCB1 SNP Predicts Outcome in Patients with Acute Myeloid Leukemia Treated with Gemtuzumab Ozagamicin: A Report from Children's Oncology Group AAML0531 Trial

Characteristics and Outcomes of Pediatric Patients with t(16;16)-AML: Results of a Case Series By the International BFM Study Group

CD33 Splicing Polymorphism Is a Strong Predictor of Therapeutic Efficacy of Gemtuzumab Ozogamicin in De Novo AML: Report from COG-AAML0531 Study

Prognostic Significance of 11q23/ MLL Fusion Partners in Children with Acute Myeloid Leukemia (AML) - Results from the Children's Oncology Group (COG) Trial AAML0531

Alteration of Chromatin Modifiers and Misregulation of Transcription Factors Define the Genomic Profile of Infant AML

The Addition of Bortezomib to Standard Chemotherapy for Pediatric Acute Myeloid Leukemia Has Increased Toxicity without Therapeutic Benefit: A Report from the Children's Oncology Group

Recurrent Genetic Abnormalities Are Reflected in Phenotype at Diagnosis in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group Protocol AAML0531

High Expression of Myocyte Enhancer Factor 2C ( MEF2C ) Is Associated with Adverse Risk Features and Poor Outcome in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group

Prevalence and Prognostic Significance of KIT Mutations in Pediatric Core Binding Factor AML Patients Treated with Gemtuzumab Ozogamicin: Results from the Randomized Phase III Children's Oncology Group Trial AAML0531

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only